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A prospeetive study of peritoneal transport in CAPD patients. A
prospective two year follow-up study of the functional characteristics of
the peritoneal membrane was conducted in 61 CAPD patients. Perito-
neal transport of solutes, calculated by mass transfer area coefficients
for urea and creatinine, peritoneal clearances for proteins, percentage
of absorption of glucose, as well as net ultrafiltration were measured
every four months. After five months on CAPD a decrease was found
for the transport of most solutes (P < 0.05, mean values, mlIminIl.73
m2): urea 18.1 to 16.2, creatinine 9,5 to 8.4, IgG 0.049 to 0.040 and
a2-macroglobulin 0.020 to 0.015, as well as for the absorption of glucose
(57.9 to 53.2%, P < 0.05). Net ultrafiltration increased simultaneously
from 44.6 to 100.5 ml/4 hr/I .73 m2, P < 0.05. From five months to two
years on CAPD a significant increase in the transport of all solutes
except a2-macroglobulin was found, as well as a decrease in net
ultrafiltration. Peritoneal transport at the end of the study was not
significantly different from the starting values. Our findings indicate an
initial effect of CAPD itself on peritoneal transport, probably due to the
recent start of the treatment. Baseline values were reached after five
months on CAPD. Thereafter a gradual increase in peritoneal solute
transport occurred during two years of treatment. This can be explained
by an increase in the effective peritoneal surface area.
Continuous ambulatory peritoneal dialysis (CAPD) has been
used as a treatment of end-stage renal failure for more than 15
years. Several studies have established that patient survival is
similar in CAPD and hemodialysis, although the technique
survival in CAPD is lower [1, 2]. Since the technique survival
has improved during recent years, the question arises as to what
extent the peritoneal membrane can maintain its function as a
dialysis membrane [31.
A number of studies has been published on the results of
longitudinal follow-up of solute transport in CAPD patients. In
these studies only the transport of low- or middle molecular
weight solutes was investigated. In one study 14 patients were
investigated during a five year period [4], but in most other
studies less than 10 patients completed a two year follow-up. In
some of these studies no changes in time were observed [4-9],
whereas in others an increase in the transport of low molecular
weight solutes was found [10—12]. Similar results were obtained
in cross sectional studies [8, 13—15].
There is general agreement about the changes in net ultrafil-
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tration in time. All studies reported a loss of the capacity for net
ultrafiltration in some patients, but the frequency of its occur-
rence varied widely [2, 11, 14, 16—20]. The incidence of loss of
net ultrafiltration capacity increased with time on CAPD [16,
20].
In a recent study we compared 20 patients with a mean
duration on CAPD of five years (range 49 to 76 months) with 20
matched patients, examined within three months after the start
of CAPD [21]. The transport of low- and middle molecular
weight solutes was higher in the long-term group than in the
recently started group, whereas the transport of a2-macroglob-
ulin, the largest protein tested, was lower in the long-term
group. The intrinsic permeability of the peritoneal membrane,
determined by the transport of macromolecules, showed a more
restricted passage in the long-term group. Also, net ultrafiltra-
tion was lower in these patients. The results obtained pointed to
the development of a larger effective peritoneal surface area
combined with a less permeable peritoneal membrane after
many years of CAPD. The following prospective long-term
follow-up study was performed to validate the results of our
earlier case-control study.
Methods
Patients
All adult patients who started CAPD from January 1986 until
December 1989 could enter the study. The patients were treated
with four to five exchanges per day using 1.5 or 2 liters of
dialysate. None of the patients had peritonitis during or in the
three weeks before the study. The patients were not treated
with erythropoietin. The protocol was approved by the medical
ethics committee of the University Hospital of Amsterdam, and
informed consent was obtained from all patients.
Study protocol
The peritoneal permeability was studied every four months
and the patients were followed for a period of two years. The
investigation was performed for the first time within three
months after the start of CAPD, usually after four to eight
weeks. The peritoneal permeability tests were done with com-
mercially available pre-warmed dialysate, glucose concentra-
tion 1.36% (Dianeal®, Baxter B .V., Utrecht, The Netherlands).
The test bag had the same dialysate volume as was used
normally. Prior to the study the abdominal cavity was rinsed
twice with dialysate that was drained immediately after inflow.
Then a fresh dialysate bag (test bag) containing 2.5 glliter inulin
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(mutest®, Laevosan-Gesellschaft, Linz/Donau, Austria) was
instilled for a dwell time of exactly four hours. After drainage of
the test bag the abdominal cavity was rinsed again. Samples
were taken from the test bag before inflow and again after
drainage. Also blood samples were taken before inflow of the
test bag and after drainage. Dialysate samples after drainage
were also obtained from the subsequent rinsing bag to calculate
the residual volume.
Determinations
Urea was measured by use of the DAM-TSC Technicon
SD4—00l DK 7 method, creatinine by the modified Jaffé method
and glucose by the glucose oxidase-peroxidase method, all
determined by autoanalyzers (Technicon SMA and SMA-Il).
Appropriate corrections were made for creatinine according to
the glucose concentration in the dialysate: creatinine corrected
(jsmoL/liter) = creatinine (mol/liter) —0.47 x glucose (mmoil
liter). Inulin was measured by a modification of Walser's
method with the color reagent diphenylamine [22], selected
because interference with the high glucose concentration of the
dialysate is absent with this method. 32-microglobulin was
determined by radioimmunoassay (Pharmacia Diagnostics AB,
Uppsala, Sweden). Albumin and IgG were measured by immu-
noturbidimetry, a2-macroglobulin by immunonephelometry us-
ing commercial antisera (Dakopatts, Gotrupp, Denmark).
Calculations
Each experiment was analyzed individually for solute trans-
port and net ultrafiltration. For urea (mol wt 60) and creatinine
(mol wt 113) solute transport was assessed by calculating mass
transfer area coefficients, that is, the maximal theoretical trans-
port by diffusion at the start of the dwell. This was done with
the use of a mathematical model assuming first order kinetics in
aqueous instead of plasma solute concentrations [23, 24]. For
132-microglobulin (mol wt 11,800), albumin (mol wt 69,000), IgG
(mol wt 150,000) and a2-macroglobulin (mol wt 820,000) solute
transport was calculated as the peritoneal clearance, that is, the
amount of protein drained, divided by the product of the mean
of the concentration of each protein in serum and the dwell
time. The glucose absorption was calculated as percentage of
the instilled quantity. In all patients the intrinsic peritoneal
permeability was assessed by the peritoneal restriction coeffi-
cient. This restriction coefficient was calculated as the slope(s)
of the power curve between the clearances of proteins and their
free diffusion coefficient in water (D20,), according to the
equation y = axe', that is: clearance = a.D20 (a is a constant)
[25, 261. Net ultrafiltration was calculated by the difference in
weight of the test bag before inflow and after drainage. Mass
transfer area coefficients, peritoneal clearances as well as net
ultrafiltration were expressed per 1.73 m2 body surface area.
The body surface area was calculated using the ideal body
weight [27]. The residual volume after drainage was calculated
using inulin as described earlier [281.
Statistical analysis
The results are given as mean values 1 standard deviation
unless mentioned otherwise. The data were analyzed by anal-
ysis of variance (ANOVA) for repeated measurements with
missing values (due to drop out) [29]. A linear trend in time was
analyzed by ANOVA, using a random coefficient growth curve
model [291. The actuarial patient survival and technique sur-
vival were calculated by life-table analysis [30]; for calculation
of technique survival only transfer to hemodialysis was consid-
ered as a failure. Also the Wilcoxon and Mann-Whitney tests
were used. The statistical analysis was done on a personal
computer using BMDP statistical software (BMDP Statistical
Software, Inc., Los Angeles, California, USA). A P value
below 0.05 (two-tailed) was considered to indicate a significant
difference.
Results
Patients
From January 1986 until December 1989, 83 patients started
CAPD. Eleven patients refused to participate in the study.
Before the first examination took place, one patient was trans-
ferred to another center, six patients were transferred to
hemodialysis and four patients died. Consequently 61 patients
(27 females and 34 males) entered the study. The median age of
these patients was 57 years, with a range of 22 to 75 years. The
causes of renal failure were glomerulonephritis in 17 patients,
pyelonephritis in 11, diabetic nephropathy in 8, nephrosclerosis
in 6, interstitial nephritis in 6, lupus nephritis in 3, polycystic
disease in 3, amyloidosis in 2, scleroderma in 1, and unknown in
4 patients.
During the follow-up period of two years 16 patients died, 15
were transplanted, 6 changed to hemodialysis, and S patients
had discontinued their participation in the study. Thus, 19
patients completed the whole study period. The patient and
technique survival is given in Figure 1A. The total drop out of
patients during the study period of two years is shown in Figure
lB. The causes of death were myocardial infarction in 8
patients, peritonitis in 5 (4 due to bowel perforation with
subsequent fecal peritonitis), intracerebral bleeding in 2 and
unknown in 1. The reasons for transfer to hemodialysis were
bowel perforation in 5 patients, and intra-abdominal adhesions
found during a second catheter implantation in 1 patient. The
median peritonitis incidence was 1.4 episodes per patient year
(range 0 to 7.8). Median time on CAPD at the first examination
was 43 days. Median time on CAPD for the consecutive
examinations is given in Table 1.
Transport characteristics
The data of the first examination after the start of CAPD are
given in Table 2. A higher solute transport and a lower net
ultrafiltration was observed one month after the start of CAPD
compared to four months later (Table 3). In these patients also
the restriction coefficient differed between the two examina-
tions (2.22 0.39 vs. 2.35 0.30, P < 0.05).
From five months to two years on CAPD an increase with
time was found in the transport of most solutes (Table 1, Fig. 2).
During this period the trend reached significance (ANOVA) for
the mass transfer area coefficients of urea (P = 0.022) and
creatinine (P = 0.005), the clearances of /32-microglobulin (P =
0.007), albumin (P 0.014), IgG (P 0.007), as well as for the
glucose absorption (P = 0.001). After a plateau phase also a
decrease was observed in net ultrafiltration (Fig. 2; P =0.031).
No trend was found for the restriction coefficient (Fig. 3).
Peritoneal transport at the end of the study did not differ
significantly from the starting values. No differences were
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found in either the transport data (Table 4) or other patient
characteristics between the patients who dropped out after the
examination at five months, compared to those who completed
the study.
No changes in time were found in the residual volume of the
patients measured using inulin; it was 246 127 ml at 43 days,
229 151 at 161 days, 223 102 at 289 days, 240 86 at 403
days, 243 159 at 529 days, 242 113 at 646 days and 274
153 ml at 777 days. No relation was found between peritonitis
incidence, hemoglobin or hematocrit and the changes in time of
solute and fluid transport characteristics.
Discussion
Peritoneal transport kinetics in CAPD patients were analyzed
in a prospective follow-up study during a period of two years.
Two different changes in time were observed. First, solute
transport was higher for most solutes one month after the
initiation of CAPD, when compared to the examination at five
months in combination with a lower intrinsic pentoneal perme-
ability. Simultaneously a lower net ultrafiltration was observed.
Second, an increase in the transport of urea, creatinine, /2-
microglobulin, albumin and IgG was found after the fifth month,
whereas no changes were observed for a2-macroglobulin. Also
the glucose absorption increased in time. A decrease in time
after the fifth month on CAPD was seen for net ultrafiltration.
The intrinsic peritoneal permeability remained unchanged. No
patient discontinued CAPD because of deterioration of the
function of the peritoneum as a dialysis membrane.
Solute transport from blood to dialysate is determined by the
peritoneal surface area and the intrinsic permeability of the
membrane. As the transport of low molecular weight solutes,
unlike macromolecules, is not hindered by a size-dependent
restriction barrier in the peritoneum [26, 31, 32], it is mainly
800 dependent on the effective peritoneal surface area. This implies
that alterations in mass transfer area coefficients of those
solutes are caused by changes in surface area, which is not a
constant property, but mainly dependent on the number of
perfused capillaries. As a consequence the mass transfer area
coefficient of low molecular weight solutes, like creatinine, can
be considered to be a functional representation of the effective
peritoneal surface area [33]. The transport of macromolecules is
size-selectively restricted [26, 34, 35],which makes it likely that
transport of serum proteins is dependent both on effective
surface area and on permeability of the peritoneal membrane.
The intrinsic permeability of this membrane to the transport of
macromolecules from the circulation to the dialysate can be
characterized by the restriction coefficient [25, 26].
Changes in net ultrafiltration can be induced by several
independent mechanisms. A decrease in transperitoneal pas-
sage of fluid can be caused by a decrease in the peritoneal
surface area available for transport processes, but this seems to
occur infrequently. Also an increase in surface area can lead to
an impaired removal of fluid. This is due to a higher absorption
800 of glucose from the dialysate, leading to a rapidly dissipating
osmotic gradient. An increase in the residual volume can also
cause a more rapid loss of osmotic gradient, as the glucose
instilled is immediately diluted with the less glucose containing
residual volume. Also a high lymphatic absorption from the
peritoneal cavity has been reported to cause a low net ultrafil-
tration [20, 36].
The transport of most solutes was higher one month after the
start of CAPD compared to four months later, together with a
lower restriction coefficient. Also a lower net ultrafiltration was
observed. These findings could therefore be explained by a
large peritoneal surface area combined with an increased peri-
toneal permeability. This phenomenon is probably caused by an
effect of the dialysis solution on the number of perfused
peritoneal capillaries, leading to an increased blood flow and
blood volume [37, 38]. An increase in the peritoneal microcir-
culation can be caused by irritation due to the fresh dialysate
[39—42], while after a few months the peritoneum is probably
adapted to the vasoactive effects of the dialysate. This hypoth-
esis is supported by the observation of a marked decrease in cell
counts in the effluent during the first months on CAPD [43—45].
Also, a similar effect of fresh dialysate on peritoneal transport
has been found in rats [46]. An increased glucose absorption
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Fig. 1. Patient (dotted line) and technique survival (solid line) (A) and
the percentage of patients present during the study (B).
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Table 1. Mass transfer area coefficients (mean Sn) of low molecular weight solutes and protein clearances measured every four months for
a period of two years, starting from the fifth month (2nd examination)
Examination
Number of patients
Median days after start of CAPD
2
42
161
3
29
289
4
27
403
5
22
529
6
17
646
7
19
777
Urea ml/min/1.73 in2
Creatinine ml/min/1.73 m2
132-microglobulin ml/min/l.73 in2
Albumin pJ/min/1.73 m2
IgG pJ/min/I.73 in2
a2-macroglobulin .d/min/1.73 m2
16.2 2.9
8.4 2.0
0.79 0.30
78.4 27.4
39.8 17.5
15.2 8.4
17.2 3.3
8.9 2.3
0.80 0.31
85.1 87.8
45,8 23.5
18.0 9.2
16.6 3.1
9.5 3.8
0.79 0.32
95,7 48.8
52.1 31.7
20.0 19.4
16.7 3.1
8.8 2.2
0.87 0.32
96.6 40.4
50.0 27.3
17.9 8.4
17.8 3.6
9.3 2.6
0.89 0.37
101,0 49.3
55.7 34.9
19.9 15.2
17.3 3,9a9.2 20
0.93
94•5 394a
54.2 25.51)
19.3 13.5
a P < 0.05 and b P < 0.01 for a positive trend for examination 2 to 7
Mean Range
Ureaml/min/J.73m2
Creatinine ml/min/1.73 m2
Glucose %
f32-microglobulin ml/min/I .73 m2
Albumin pilmin/1.73 m2
IgG pJ/min/I.73 in2
a2-macroglobulin pJ/min/1.73 m2
Net ultrafiltration ml/4 hr/I .73 m2
Restriction coefficient
18.2
9.9
60.0
0.97
95.5
53.0
21.4
22.0
2.256
11.6—31.8
4.3—19.0
31.2—83.0
0.34—2.52
40.7—223.0
13,7—116.5
3.7—68.9
—453.6-426,4
1,337—3.292
from the peritoneal cavity combined with a decreased fluid
removal was observed after a six week period of twice daily
intrapentoneal injections of fresh dialysate in these animals
compared to a control group. The findings of the present study
indicate that baseline values for evaluation of peritoneal mem-
brane function, should not be obtained before three months
after the start of CAPD. The conflicting data from previous
investigations may partly be explained by the differences in the
timing of the baseline measurements.
From five months to two years on CAPD an increase was
found for the transport of all solutes except for a2-macroglob-
ulin and a decrease in net ultrafiltration, whereas the restriction
coefficient remained unchanged. These results can be explained
by an increase in peritoneal surface area, possibly caused by an
increase in the extensiveness of the peritoneal capillary net-
work or alternatively in the number of capillaries perfused.
In our earlier case-control study the transport of creatinine
and glucose was higher and net ultrafiltration was lower after at
least four years of treatment [21]. This probably indicates that
the increase in peritoneal surface area will continue after two
years of treatment, as in the present study solute transport after
two years was only about equal to the values obtained during
the first examination. In the case-control study the intrinsic
peritoneal permeability was decreased after more than four
years of CAPD, as reflected by a lower clearance of a2-
macroglobulin and a lower peritoneal restriction coefficient. In
the present prospective study only the transport of a2-macro-
globulin showed no significant increase after its initial drop.
This suggests that also in these patients a decrease in the
intrinsic permeability could occur after a duration of treatment
in excess of two years.
The possibility must be considered that an increase in hemo-
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Fig. 2. Glucose absorption (mean 5EM, %) and net ultrafiltration
(ml/4 hr/I .73 m2), measured every four months in 61 CAPD patieitts for
a period of two years. The median days at each interval are given. The
symbol # indicates a significant difference between day 43 and 161,
whereas * symbolizes a significant trend from day 161 to 777.
globin and hematocrit during the first year of CAPD explains
the results during the first five months on CAPD, as Korbet et
al found a negative correlation between the transport of creat-
mine and hematocrit in eight patients during treatment with
erythropoietin [47]. However, others were unable to demon-
strate a relation between transport kinetics and hemoglobin [48,
49]. Also in the present prospective study no relation was found
between both parameters and the changes observed in time for
the transport of solutes or net ultrafiltration.
The peritonitis incidence in this patient group was 1.4 epi-
sodes per patient per year with the use of the standard CAPD
Table 2. Mass transfer area coefficients (mean range) of low
molecular weight solutes, glucose absorption, protein clearances, net
ultrafiltration and peritoneal restriction of the 61 patients examined
examined the first time after the start of CAPD
A
62
B
52 -
160
120
80
40
0
—40 F I I I I I I
43 161 289 403 529 646 777
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First examination Second examination P
Urea mi/mini 18.1 4.3 16.2 2.9 0.002
1.73 m2
Creatinine mu 9.5 3.9 8.4 2.0 0.003
min/l.73 m2
Glucose % 57.9 11.7 53.2 9.5 0.001
-microglobu1in mu
minil.73 m2
0.87 0.38 0.79 0.30 0.1
Albumin d/
min/1.73 m2
89.0 36.6 78.4 27.4 0.06
IgG pjimin/1.73 m2 49.1 23.7 39.7 17.5 0.005
a2-macroglobulin
j.tl/min/1.73 m2
20.4 14.4 15.2 8.4 0.03
Net ultraffitration 44.6 118.4 100.5 163.8 0.05
mli4 hril.73 m2
21 1 1 E I I
1T T f
161 289 403 529 646 777
Time after start CAPD, days
Fig. 3. Peritoneal restriction coefficient (mean SEM), calculated
every four months in 42 CAPD patients for a period of two years,
starting from the second examination. No significant changes were
found.
system. Alter changing to the twinbag system the peritonitis
incidence dropped to 0.7 episodes per patient per year. During
the study period an unusually high incidence of peritonitis due
to bowel perforations was found. This high incidence cannot be
explained and is in contrast to our previous experience. From
July 1979 until December 1992, fecal peritonitis was seen 25
times on a total of 1050 peritonitis episodes, which was an
incidence of 2%.
In conclusion, our findings indicate an initial effect of CAPD
on peritoneal transport, probably due to the recent start of the
treatment. Baseline values were reached after five months on
CAPD, followed by a gradual increase in peritoneal solute
transport and a decrease in net ultrafiltration during two years
of treatment. This can be explained by an increase in effective
peritoneal surface area. Despite these modest changes, the
peritoneum maintained its function as a dialysis membrane
Urea ml/min/i.73 m2 15.5 3.1 16.7 2.8
Creatinine mliminil.73 m2 8.4 2.0 8.5 2.1
Glucose % 53.9 8.4 52.8 10.4
/32-microglobulin mlimin/I.73 m2
Albumin pJ/min/i.73 m2
IgG jsl/min/i.73 in2
a2-macroglobulin piimin/1.73 in2
Net ultrafiltration ml/4 hr/i .73 in2
0.77 0.33
78.3 32.4
39.8 21.4
14.6 9.8
83.4 177.8
0.80 0.28
78.4 24.1
39.7 14.9
15.6 7.5
112.1 156.2
during the study period. Whether the observed changes in
pentoneal transport can be influenced needs further study.
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